Exelixis Inc Revenue Growth Rates (EXEL), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Exelixis Inc   (NASDAQ: EXEL)
 

EXEL's Revenue Growth by Quarter and Year

Exelixis Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/EXEL/growth
https://api.csimarket.com/api/v1/companies/EXEL/fundamentals
https://api.csimarket.com/api/v1/companies/EXEL/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
EXEL Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter January -
3rd Quarter October 658.70
2nd Quarter July 628.69
1st Quarter April 610.81
FY 1,898.20

EXELs Annual Revenue
Exelixis Inc 's Revenue in the fiscal year 2025 $ 2,320.13 millions
Exelixis Inc 's Revenue in the fiscal year 2024 $ 2,168.70 millions
Exelixis Inc 's Revenue in the fiscal year 2023 $ 1,830.21 millions
Exelixis Inc 's Revenue in the fiscal year 2022 $ 1,611.06 millions
Exelixis Inc 's Revenue in the fiscal year 2021 $ 1,434.97 millions




EXEL Revenue third quarter 2026 Y/Y Growth Comment
Exelixis Inc reported Revenue increase of 10.19% year on year in the third quarter 2026, to $ 658.70 millions, this is lower than Exelixis Inc 's recent average Revenue rise of 47.32%.

Looking into third quarter 2026 results within Biotechnology & Pharmaceuticals industry 42 other companies have achieved higher Revenue growth. While Exelixis Inc ' s Revenue growth of 10.19% ranks overall at the positon no. 2892 in the third quarter 2026.


EXEL Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter January -
3rd Quarter October 10.19 %
2nd Quarter July 10.63 %
1st Quarter April 9.97 %
FY   -

Financial Statements
Exelixis Inc 's third quarter 2026 Revenue $ 658.70 millions EXEL's Income Statement
Exelixis Inc 's third quarter 2025 Revenue $ 597.76 millions Quarterly EXEL's Income Statement


EXEL Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter January -
3rd Quarter October 4.77 %
2nd Quarter July 2.93 %
1st Quarter April 2.03 %
FY (Year on Year)   -


Back to EXEL Growth rate Comparisons >> Back to EXEL Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #43
Healthcare Sector #406
Overall #2892

Revenue Y/Y Growth Statistics
High Average Low
494.56 % 47.32 % -85.87 %
(Mar 31 2017)   (Mar 31 2013)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #43
Healthcare Sector #406
Overall #2892
Revenue Y/Y Growth Statistics
High Average Low
494.56 % 47.32 % -85.87 %
(Mar 31 2017)   (Mar 31 2013)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Exelixis Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
298.83 % 12.03 % -80.37 %
(Sep 30 2011)  


EXEL's III. Quarter Q/Q Revenue Comment
Exelixis Inc achieved in the III. Quarter 2026 below company average Revenue growth of 4.77% quarter on quarter, to $ 658.70 millions.

Within Biotechnology & Pharmaceuticals industry 25 other companies have achieved higher Revenue quarter on quarter growth. While Exelixis Inc 's Revenue growth quarter on quarter, overall rank is 1359.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #26
Healthcare Sector #189
Overall #1359
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #26
Healthcare Sector #189
Overall #1359
Revenue Q/Q Growth Statistics
High Average Low
298.83 % 12.03 % -80.37 %
(Sep 30 2011)  


EXEL's III. Quarter Q/Q Revenue Comment
Exelixis Inc achieved in the III. Quarter 2026 below company average Revenue growth of 4.77% quarter on quarter, to $ 658.70 millions.

Within Biotechnology & Pharmaceuticals industry 25 other companies have achieved higher Revenue quarter on quarter growth. While Exelixis Inc 's Revenue growth quarter on quarter, overall rank is 1359.


Exelixis Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Oct 02 2026)		 12 Months Ending (Jul 03 2026) 12 Months Ending (Apr 03 2026) 12 Months Ending (Jan 02 2026) 12 Months Ending (Oct 03 2025)
Cumulative Revenue 12 Months Ending $ 2,496.86
Y / Y Revenue Growth (TTM) 9.12 %
Year on Year Revenue Growth Overall Ranking # 1424
Seqeuential Revenue Change (TTM) 2.5 %
Seq. Revenue Growth (TTM) Overall Ranking # 2892


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Oct 02 2026 period, Exelixis Inc 's cumulative twelve months Revenue were $ 2,497 millions, company would post below average annual Revenue growth of 2.5% year on year, if the fiscal year would end at Oct 02 2026.
A slow-down in the Exelixis Inc 's Revenue growth from the 628.69% growth in Jul 03 2026.

In the Healthcare sector 241 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 562 to 1424.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 43
Healthcare Sector # 242
Overall # 1424

Revenue TTM Y/Y Growth Statistics
High Average Low
494.56 %
 47.32 %
-85.87 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 43
Sector # 406
S&P 500 # 2892
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Oct 02 2026 period, Exelixis Inc 's cumulative twelve months Revenue were $ 2,497 millions, company would post below average annual Revenue growth of -85.87% year on year, if the fiscal year would end at Oct 02 2026.
A slow-down in the Exelixis Inc 's Revenue growth from the 628.69% growth in Jul 03 2026.

In the Healthcare sector 241 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 562 to 1424.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 43
Healthcare Sector # 242
Overall # 1424

Revenue TTM Y/Y Growth Statistics
High Average Low
494.56 %
47.32 %
-85.87 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 43
Sector # 406
S&P 500 # 2892




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
EXEL's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Oct 02 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Oct 02 2026
Exelixis Inc 10.19%$ 10.195 millions


About Exelixis Inc Revenue Growth Rates (EXEL), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Exelixis Inc (CIK 939767).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000939767-26-000116
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Exelixis Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.